{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:39:08Z","timestamp":1773679148157,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,16]]},"DOI":"10.7759\/cureus.105324","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:36:54Z","timestamp":1773675414000},"source":"Crossref","is-referenced-by-count":0,"title":["Tocilizumab as a Potential Alternative Therapy for Acute Exacerbation of Systemic Sclerosis-Associated Interstitial Lung Disease in a Dialysis Patient Following Immunodeficiency-Associated Lymphoproliferative Disorders"],"prefix":"10.7759","author":[{"given":"Taiga","family":"Kuga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makio","family":"Kusaoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Yamaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/2397198320915042","article-title":"Update on morbidity and mortality in systemic sclerosis-related interstitial lung disease","volume":"6","author":"Volkmann ER","year":"2021","unstructured":"Volkmann ER, Fischer A. Update on morbidity and mortality in systemic sclerosis-related interstitial lung disease. J Scleroderma Relat Disord. 2021, 6:11-20. 10.1177\/2397198320915042","journal-title":"J Scleroderma Relat Disord"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin DP","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, et al.. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016, 4:708-19. 10.1016\/s2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow SH","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al.. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016, 127:2375-90. 10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2020.08.011","article-title":"Rare oral presentation of a mycophenolate mofetil-related other iatrogenic immunodeficiency-associated lymphoproliferative disorder (MMF-OIA-LPD) lesion: a case report and literature review","volume":"79","author":"Taliaferro A","year":"2021","unstructured":"Taliaferro A, Samhouri Y, Rice J, Khan CM, Cillo JE. Rare oral presentation of a mycophenolate mofetil-related other iatrogenic immunodeficiency-associated lymphoproliferative disorder (MMF-OIA-LPD) lesion: a case report and literature review. J Oral Maxillofac Surg. 2021, 79:398-403. 10.1016\/j.joms.2020.08.011","journal-title":"J Oral Maxillofac Surg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo F","year":"2025","unstructured":"Del Galdo F, Lescoat A, Conaghan PG, et al.. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis. 2025, 84:29-40. 10.1136\/ard-2024-226430","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna D","year":"2018","unstructured":"Khanna D, Denton CP, Lin CJ, et al.. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis. 2018, 77:212-20. 10.1136\/annrheumdis-2017-211682","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna D","year":"2020","unstructured":"Khanna D, Lin CJF, Furst DE, et al.. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020, 8:963-74. 10.1016\/S2213-2600(20)30318-0","journal-title":"Lancet Respir Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1022769","article-title":"Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal","volume":"56","author":"Inui Y","year":"2015","unstructured":"Inui Y, Matsuoka H, Yakushijin K, et al.. Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal. Leuk Lymphoma. 2015, 56:3045-51. 10.3109\/10428194.2015.1022769","journal-title":"Leuk Lymphoma"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000213","article-title":"Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab","volume":"2","author":"Rubbert-Roth A","year":"2016","unstructured":"Rubbert-Roth A, Sebba A, Brockwell L, et al.. Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab. RMD Open. 2016, 2:e000213. 10.1136\/rmdopen-2015-000213","journal-title":"RMD Open"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-005247","article-title":"Cancer recurrence risk with bDMARD treatment in patients with rheumatoid arthritis and a history of cancer: a nationwide Danish register-based cohort study","volume":"11","author":"Westermann R","year":"2025","unstructured":"Westermann R, Cordtz R, Duch K, Mellemkjaer L, Hetland ML, Rasmussen LA, Dreyer L. Cancer recurrence risk with bDMARD treatment in patients with rheumatoid arthritis and a history of cancer: a nationwide Danish register-based cohort study. RMD Open. 2025, 11:10.1136\/rmdopen-2024-005247","journal-title":"RMD Open"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/23971983251324803","article-title":"Physician-patient communication in the treatment of systemic sclerosis-associated interstitial lung disease: a narrative review and recommendations","volume":"10","author":"Kuwana M","year":"2025","unstructured":"Kuwana M, Saito A, Farrington S, Galetti I, Denton CP, Khanna D. Physician-patient communication in the treatment of systemic sclerosis-associated interstitial lung disease: a narrative review and recommendations. J Scleroderma Relat Disord. 2025, 10:224-36. 10.1177\/23971983251324803","journal-title":"J Scleroderma Relat Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton CP","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017, 390:1685-99. 10.1016\/s0140-6736(17)30933-9","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5301\/jsrd.5000266","article-title":"Interleukin-6 and related proteins as biomarkers in systemic sclerosis","volume":"2","author":"Denton CP","year":"2017","unstructured":"Denton CP, Ong VH. Interleukin-6 and related proteins as biomarkers in systemic sclerosis. J Scleroderma Relat Disord. 2017, 2:S13-9. 10.5301\/jsrd.5000266","journal-title":"J Scleroderma Relat Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/467403-tocilizumab-as-a-potential-alternative-therapy-for-acute-exacerbation-of-systemic-sclerosis-associated-interstitial-lung-disease-in-a-dialysis-patient-following-immunodeficiency-associated-lymphoproliferative-disorders","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:36:55Z","timestamp":1773675415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/467403-tocilizumab-as-a-potential-alternative-therapy-for-acute-exacerbation-of-systemic-sclerosis-associated-interstitial-lung-disease-in-a-dialysis-patient-following-immunodeficiency-associated-lymphoproliferative-disorders"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.105324","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,16]]}}}